-
公开(公告)号：US08901356B2
公开(公告)日：2014-12-02
申请号：US13811207
申请日：2011-07-08
申请人： Thomas Högberg , Gunnar Grue-Sørensen , Xifu Liang , Anne Marie Horneman , Anders Klarskov Petersen
发明人： Thomas Högberg , Gunnar Grue-Sørensen , Xifu Liang , Anne Marie Horneman , Anders Klarskov Petersen
IPC分类号： C07C49/753 , C07C59/90 , C07C67/08 , C07D319/08 , C07F7/18 , C07C67/297
CPC分类号： C07C67/08 , C07C49/753 , C07C59/90 , C07C67/14 , C07C67/297 , C07C2603/86 , C07C2603/98 , C07D317/70 , C07D319/08 , C07D493/08 , C07F7/1804 , Y02P20/55 , C07C69/533
摘要： The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.
摘要翻译： 本发明涉及从烯醇（II）生产西内醇-3-天竺葵酸（I）的方法。 此外，本发明涉及可用于合成来自烯醇（II）的内酯-3-通配物（I）的中间体以及制备所述中间体的方法。
-
公开(公告)号：US20130177952A1
公开(公告)日：2013-07-11
申请号：US13811207
申请日：2011-07-08
申请人： Thomas Högberg , Gunnar Grue-Sørensen , Xifu Liang , Anne Marie Horneman , Anders Klarskov Petersen
发明人： Thomas Högberg , Gunnar Grue-Sørensen , Xifu Liang , Anne Marie Horneman , Anders Klarskov Petersen
IPC分类号： C07C49/753 , C07C59/90 , C07C67/08 , C07D319/08 , C07F7/18
CPC分类号： C07C67/08 , C07C49/753 , C07C59/90 , C07C67/14 , C07C67/297 , C07C2603/86 , C07C2603/98 , C07D317/70 , C07D319/08 , C07D493/08 , C07F7/1804 , Y02P20/55 , C07C69/533
摘要： The present invention relates to methods of producing ingenol-3-angelate (I) from ingenol (II). Furthermore, the invention relates to intermediates useful for the synthesis of ingenol-3-angelate (I) from ingenol (II) and to methods of producing said intermediates.
-
公开(公告)号：US09102687B2
公开(公告)日：2015-08-11
申请号：US13996989
申请日：2011-12-22
申请人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg , Kristoffer Månsson , Per Vedsø , Thomas Vifian
发明人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg , Kristoffer Månsson , Per Vedsø , Thomas Vifian
IPC分类号： C07D405/06 , C07D513/04 , C07C271/34 , C07C271/36 , C07C271/38 , C07D249/06 , C07D261/18 , C07D277/32 , C07D295/21 , C07D309/08 , C07D333/38 , C07D401/04 , C07D471/04 , C07D495/04 , C07D265/36 , C07D271/08 , C07D277/587 , C07D295/205 , C07D307/00 , C07D307/94
CPC分类号： C07D261/18 , A61K31/365 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/472 , A61K31/502 , A61K31/5375 , A61K31/538 , C07C271/34 , C07C271/36 , C07C271/38 , C07C2603/86 , C07D209/08 , C07D209/42 , C07D213/79 , C07D215/50 , C07D217/26 , C07D231/14 , C07D231/56 , C07D233/90 , C07D237/28 , C07D239/28 , C07D249/04 , C07D249/06 , C07D261/20 , C07D263/34 , C07D265/36 , C07D271/08 , C07D277/32 , C07D277/56 , C07D277/587 , C07D295/182 , C07D295/205 , C07D295/21 , C07D307/00 , C07D307/68 , C07D307/94 , C07D309/08 , C07D333/38 , C07D333/40 , C07D401/04 , C07D405/06 , C07D471/04 , C07D493/08 , C07D495/04 , C07D513/04
摘要： The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
摘要翻译： 本发明涉及通式I的化合物，其中R是任选被R 7取代的杂芳基; 或R是任选被R 8取代的杂环烷基或杂环烯基; 或R为X，其中X为-NR 11 R 12; 其药学上可接受的盐，水合物或溶剂合物，用于单独或与一种或多种其它药学活性化合物组合用于治疗，用于预防，治疗或改善响应刺激的中性粒细胞氧化性突发的反应的疾病或病症 的角质形成细胞IL-8释放或响应于坏死的诱导。
-
公开(公告)号：US20130324600A1
公开(公告)日：2013-12-05
申请号：US13996549
申请日：2011-12-22
申请人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg
发明人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg
IPC分类号： C07C255/41 , C07C251/44 , C07C69/533
CPC分类号： C07C255/41 , C07C69/013 , C07C69/24 , C07C69/533 , C07C69/54 , C07C69/60 , C07C69/608 , C07C69/614 , C07C69/616 , C07C69/618 , C07C233/56 , C07C251/44 , C07C251/48 , C07C255/23 , C07C2601/14 , C07C2603/86
摘要： The invention relates to compounds of general formula (I) wherein R is (C1-C7)alkyl, (C2-C7)alkenyl or (C2-C7)alkynyl; wherein R is substituted with R1; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
摘要翻译： 本发明涉及通式（I）的化合物，其中R是（C 1 -C 7）烷基，（C 2 -C 7）烯基或（C 2 -C 7）炔基; 其中R被R 1取代; 其药学上可接受的盐，水合物或溶剂合物，用于单独或与一种或多种其它药学活性化合物组合用于治疗，用于预防，治疗或改善响应刺激的中性粒细胞氧化性突发的反应的疾病或病症 的角质形成细胞IL-8释放或响应于坏死的诱导。
-
5.发明申请公开(公告)号：US20140303150A1
公开(公告)日：2014-10-09
申请号：US13996989
申请日：2011-12-22
申请人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg , Kristoffer Månsson , Per Vedsø , Thomas Vifian
发明人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg , Kristoffer Månsson , Per Vedsø , Thomas Vifian
IPC分类号： C07D513/04 , C07D333/38 , C07D471/04 , C07D401/04 , C07D265/36 , C07D405/06 , C07D271/08 , C07D277/587 , C07D295/205 , C07D307/00 , C07D307/94
CPC分类号： C07D261/18 , A61K31/365 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/416 , A61K31/4192 , A61K31/42 , A61K31/472 , A61K31/502 , A61K31/5375 , A61K31/538 , C07C271/34 , C07C271/36 , C07C271/38 , C07C2603/86 , C07D209/08 , C07D209/42 , C07D213/79 , C07D215/50 , C07D217/26 , C07D231/14 , C07D231/56 , C07D233/90 , C07D237/28 , C07D239/28 , C07D249/04 , C07D249/06 , C07D261/20 , C07D263/34 , C07D265/36 , C07D271/08 , C07D277/32 , C07D277/56 , C07D277/587 , C07D295/182 , C07D295/205 , C07D295/21 , C07D307/00 , C07D307/68 , C07D307/94 , C07D309/08 , C07D333/38 , C07D333/40 , C07D401/04 , C07D405/06 , C07D471/04 , C07D493/08 , C07D495/04 , C07D513/04
摘要： The invention relates to compounds of general formula I wherein R is heteroaryl optionally substituted by R7; or R is heterocycloalkyl or heterocycloalkenyl, optionally substituted by R8; or R is X wherein X is —NR11R12; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
摘要翻译： 本发明涉及通式I的化合物，其中R是任选被R 7取代的杂芳基; 或R是任选被R 8取代的杂环烷基或杂环烯基; 或R为X，其中X为-NR 11 R 12; 其药学上可接受的盐，水合物或溶剂合物，用于单独或与一种或多种其它药学活性化合物组合用于治疗，用于预防，治疗或改善响应刺激的中性粒细胞氧化性突发的反应的疾病或病症 的角质形成细胞IL-8释放或响应于坏死的诱导。
-
公开(公告)号：US09656945B2
公开(公告)日：2017-05-23
申请号：US13997011
申请日：2011-12-22
IPC分类号： C07C69/013 , C07C69/74 , C07C69/75 , C07C69/753 , C07C69/76 , C07C69/78 , C07C69/92 , A61K31/215 , A61K31/235 , A61K31/245 , C07C229/56 , C07C229/58 , C07C229/64 , C07C233/54 , C07C255/46 , A61K31/277 , A61K45/06
CPC分类号： C07C69/74 , A61K31/215 , A61K31/235 , A61K31/245 , A61K31/277 , A61K45/06 , C07C69/013 , C07C69/75 , C07C69/753 , C07C69/76 , C07C69/78 , C07C69/92 , C07C229/56 , C07C229/58 , C07C229/64 , C07C233/54 , C07C255/46 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2603/86
摘要： The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
-
公开(公告)号：US09388124B2
公开(公告)日：2016-07-12
申请号：US13996549
申请日：2011-12-22
申请人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg
发明人： Gunnar Grue-Sørensen , Xifu Liang , Thomas Högberg
IPC分类号： C07C251/44 , C07C233/56 , C07C251/48 , C07C255/23 , C07C255/41 , C07C69/013 , C07C69/24 , C07C69/533 , C07C69/54 , C07C69/608 , C07C69/614 , C07C69/616 , C07C69/60 , C07C69/618
CPC分类号： C07C255/41 , C07C69/013 , C07C69/24 , C07C69/533 , C07C69/54 , C07C69/60 , C07C69/608 , C07C69/614 , C07C69/616 , C07C69/618 , C07C233/56 , C07C251/44 , C07C251/48 , C07C255/23 , C07C2601/14 , C07C2603/86
摘要： The invention relates to compounds of general formula (I) wherein R is (C1-C7)alkyl, (C2-C7)alkenyl or (C2-C7)alkynyl; wherein R is substituted with R1; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
摘要翻译： 本发明涉及通式（I）的化合物，其中R是（C 1 -C 7）烷基，（C 2 -C 7）烯基或（C 2 -C 7）炔基; 其中R被R 1取代; 其药学上可接受的盐，水合物或溶剂合物，用于单独或与一种或多种其它药学活性化合物组合用于治疗，用于预防，治疗或改善响应刺激的中性粒细胞氧化性突发的反应的疾病或病症 的角质形成细胞IL-8释放或响应于坏死的诱导。
-
公开(公告)号：US20130331446A1
公开(公告)日：2013-12-12
申请号：US13997011
申请日：2011-12-22
IPC分类号： C07C69/74 , A61K45/06 , C07C69/75 , C07C255/46 , C07C229/56 , C07C69/78 , A61K31/235 , C07C69/76 , C07C229/64 , A61K31/245 , A61K31/215 , A61K31/277
CPC分类号： C07C69/74 , A61K31/215 , A61K31/235 , A61K31/245 , A61K31/277 , A61K45/06 , C07C69/013 , C07C69/75 , C07C69/753 , C07C69/76 , C07C69/78 , C07C69/92 , C07C229/56 , C07C229/58 , C07C229/64 , C07C233/54 , C07C255/46 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/16 , C07C2603/86
摘要： The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.
摘要翻译： 本发明涉及通式I（I）的化合物，其中R是其中R是被R3取代的芳基; 或R 3为（C 3 -C 13） - 环烷基，（C 3 -C 13） - 环烯基或任选被R 4取代的（C 7 -C 13） - 环炔基; 其药学上可接受的盐，水合物或溶剂合物，用于单独或与一种或多种其它药学活性化合物组合用于治疗，用于预防，治疗或改善响应刺激的中性粒细胞氧化性突发的反应的疾病或病症 的角质形成细胞IL-8释放或响应于坏死的诱导。
-
公开(公告)号：US07977387B2
公开(公告)日：2011-07-12
申请号：US10563474
申请日：2004-07-09
申请人： Erik Rytter Ottosen , Anne Marie Horneman , Xifu Liang , Søren Christian Schou , Sophie Elisabeth Havez , Thomas Peter Sabroe
发明人： Erik Rytter Ottosen , Anne Marie Horneman , Xifu Liang , Søren Christian Schou , Sophie Elisabeth Havez , Thomas Peter Sabroe
IPC分类号： A61K31/136 , A61K31/12 , C07C211/56 , C07C49/303
CPC分类号： C07C225/22 , C07C233/43 , C07C235/16 , C07C235/20 , C07C235/64 , C07C237/30 , C07C237/32 , C07C237/34 , C07C237/36 , C07C237/38 , C07C237/40 , C07C243/38 , C07C245/24 , C07C247/04 , C07C255/58 , C07C259/10 , C07C271/20 , C07C271/28 , C07C271/38 , C07C275/40 , C07C275/42 , C07C311/08 , C07C311/13 , C07C311/16 , C07C311/17 , C07C311/18 , C07C311/21 , C07C311/29 , C07C311/39 , C07C311/40 , C07C311/41 , C07C311/46 , C07C317/44 , C07C323/60 , C07C337/06 , C07C2601/08 , C07C2601/14 , C07D207/27 , C07D213/40 , C07D233/76 , C07D239/22 , C07D249/06 , C07D257/04 , C07D263/14 , C07D277/24 , C07D277/54 , C07D285/12 , C07D285/135 , C07D307/14 , C07D307/52 , C07D307/54 , C07D309/12 , C07D317/22 , C07D333/38 , C07D405/12
摘要： The invention provides novel compounds according to formula I relates to compounds with the general formula I said compounds being useful, e.g. in the treatment of inflammatory, ophthalmic diseases or cancer.
摘要翻译： 本发明提供了根据式I的新化合物涉及具有通式I的化合物，所述化合物是有用的，例如， 在治疗炎症，眼科疾病或癌症。
-
10.发明授权VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof 有权VEGF-2受体和蛋白酪氨酸激酶抑制剂及其药物用途公开(公告)号：US08350026B2
公开(公告)日：2013-01-08
申请号：US13058797
申请日：2009-08-27
申请人： Jakob Felding , Xifu Liang , Anne Marie Horneman , Tina Dahlerup Poulsen , Jens Christian Højland Larsen
发明人： Jakob Felding , Xifu Liang , Anne Marie Horneman , Tina Dahlerup Poulsen , Jens Christian Højland Larsen
IPC分类号： C07D213/72 , C07D405/12 , C07D413/06 , C07D413/12
CPC分类号： C07D213/75 , C07D405/12 , C07D413/12
摘要： The invention relates to compounds of general formula (I) wherein W, D, E, G, J, L, R1, R2, R3, R4, R5 and Y are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for treating diseases associated with deregulated angiogenesis, such as cancer and skin and eye diseases.
摘要翻译： 本发明涉及其中W，D，E，G，J，L，R 1，R 2，R 3，R 4，R 5和Y如本文所定义的通式（I）的化合物及其药学上可接受的盐，水合物或溶剂合物 在治疗中单独使用或与一种或多种其它药物活性化合物组合用于治疗与失调的血管生成相关的疾病，例如癌症和皮肤和眼睛疾病。
-
-
-
-
-
-
-
-
-
搜索结果
16 条记录 (耗时 0.026 秒)
